远程医疗服务提供商Hims & Hers Health Inc.（HIMS）今日盘前股价大幅下跌7.16%，引发了市场广泛关注。
消息面上，公司公布的2025年第四季度营收虽同比增长28%，但其给出的2026年第一季度营收指引仅为6亿至6.25亿美元，低于市场普遍预期的6.5259亿美元，这一令人失望的业绩展望是导致股价承压的主要原因。此外，根据公司提交给美国证券交易委员会（SEC）的文件显示，目前尚不清楚美国食品和药物监督管理局（FDA）、美国卫生与公众服务部（HHS）或司法部（DOJ）可能对复合GLP-1产品的营销采取何种监管行动，这一不确定性进一步加剧了投资者的担忧情绪。
Hims & Hers Health的减重业务是其关键增长领域，任何潜在的监管变化都可能影响公司未来营收。同时，公司还面临来自诺和诺德（NVO）的专利诉讼，多重因素共同导致了此次股价的显著下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.